PRTA News and Press, Prothena Corporation plc From 11/02/22

Summary The Clinical Trials on Alzheimer’s Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen. This conference...

DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and f...

Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which is estimated to increase to around 13.8 million by 2060. W...

Summary Acumen has ACU193, an anti-amyloid oligomer antibody and its only drug candidate, in a Phase 1 trial. The Eisai news on lecanemab led to Acumen’s share price more than doubling. ACU193's mechanism of action builds on scientific publications identifying amyloid o...

Summary I last covered Prothena in July 2021 after its stock price had surged due to the approval of Biogen's Alzheimer's drug Aduhelm. The share price slumped as Aduhelm struggled but Biogen's latest data for anti-amyloid candidate Lecanemab has triggered a surge. Prothena ha...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: MaggioPH / Shutterstock.com LiveWire (NYSE: LVWR ) stock is in the news Wednesday as the electric motorcycle company makes its trading debut today . That debut comes after the company completed its sp...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Atthapon Raksthaput / Shutterstock.com Prothena (NASDAQ: PRTA ) stock is seeing massive gains on Wednesday despite a lack of news from the late-stage clinical company. However, there is news from Biog...

Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating A...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time for another dive into the biggest pre-market stock movers as we check out what’s going on on Wednesday morning. Moving shares this morning are clinical trial...

Summary Electrovaya, an early dotcom child, managed to outlive its vigorous competition and develop one of today's leading battery technologies. Over the previous years, the company’s scale-up efforts failed. History could repeat itself as the management lacks manufacturing...